MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017

September 21, 2017 — MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study were presented at the Heart Failure Society of America (HFSA) 21st Annual Scientific Meeting, Sept. 16-19 in Dallas. PIONEER-HCM was a study of mavacamten in symptomatic, obstructive hypertrophic cardiomyopathy (oHCM) patients. In an oral presentation as part of the “Big Trials of the Last Year” session at HFSA, Stephen Heitner, M.D., director of the HCM Clinic at Oregon Health and Science University’s Knight Cardiovascular Institute, and the lead investigator in the PIONEER-HCM study, presented new time-…